Rick Randall’s initial foray into leading a Medtech company represented a bit of a fairy tale. But his next chapter – starting and leading spine company Trans1 – serves as a bit of a Medtech nightmare.
In part two of this interview, Randall walks us through the rise and fall of Trans1, the developer of a novel spine fusion approach that he brought from a one-person start-up to an emerging player in the competitive spine space.
Trans1’s fortunes changed drastically, however, when specialist societies took aim at the company’s reimbursement code, a chilling move that still can be felt in Medtech.
Randall also explains why he sees enormous opportunity for the robotic-assisted surgery upstart Omnilife Science and explains why he’s cheering for sector leader Stryker.